RecruitingNot Applicable

A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center

United States500 participantsStarted 2023-05-13

Plain-language summary

Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure
✓. An increase in serum Cr of ≥0.3 mg/dL within 48 hours or ≥50% from baseline value and/or urinary output ≤0.5 mL/kg of body weight for ≥6 hours (requires use of a urinary catheter)
✓. No full or partial response for ≥2 days of diuretic withdrawal and volume expansion with albumin (dosed at 1 g/kg of body weight/day)
✓. Absence of shock
✓. No current or recent treatment with nephrotoxic drugs
✓. Absence of parenchymal renal disease
✓. Suggestion of renal vasoconstriction based on FENa \<0.2%

What they're measuring

Primary Outcome for HRS-AKI patients

Timeframe: 4 years

Trial details

NCT IDNCT06095440

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-05-13

Contact for this trial

Colette Ngo Ndjom, MS

214-947-1281 MHSIRB@mhd.com

View on ClinicalTrials.gov More Hepatorenal Syndrome trials